IMCR (Immunocore Holdings) ROC (Joel Greenblatt) %: 130.69% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMCR Immunocore Holdings PLC IMCR
76 GF Score
Price $35.54
GF Value $46.28
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Immunocore Holdings ROC (Joel Greenblatt) %?

Immunocore Holdings IMCR +3.07% 76 ROC (Joel Greenblatt) % is 130.69% as of Mar. 2026. GuruFocus rates IMCR with a GF Score™ of 76/100 and a GF Value™ of $46.28 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,323 Biotechnology companies, Immunocore Holdings ranks better than 79.37% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Immunocore Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 130.69%.

The historical rank and industry rank for Immunocore Holdings's ROC (Joel Greenblatt) % or its related term are showing as below:

IMCR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -418.4   Med: -162.36   Max: 1.61
Current: 1.61

During the past 8 years, Immunocore Holdings's highest ROC (Joel Greenblatt) % was 1.61%. The lowest was -418.40%. And the median was -162.36%.

IMCR's ROC (Joel Greenblatt) % is ranked better than
79.37% of 1323 companies
in the Biotechnology industry
Industry Median: -297.52 vs IMCR: 1.61

Immunocore Holdings's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 39.00% per year.


Immunocore Holdings  (NAS:IMCR) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Immunocore Holdings ROC (Joel Greenblatt) % Related Terms


Immunocore Holdings ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Immunocore Holdings's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunocore Holdings ROC (Joel Greenblatt) % Chart

Immunocore Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -375.74 -87.22 -136.76 -75.37 -14.15

Immunocore Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76.20 -59.29 23.07 -90.23 130.69

IMCR vs MAZE, DMRA, AVBP: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Immunocore Holdings's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunocore Holdings ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunocore Holdings's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Immunocore Holdings's ROC (Joel Greenblatt) % falls into.


IMCR
76GF Score
Immunocore Holdings PLC IMCR
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunocore Holdings ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(73.977 + 6.742 + 24.726) - (227.566 + 0.583 + 16.542)
=-139.246

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(81.068 + 8.253 + 69.59) - (232.316 + 0.572 + 5.229)
=-79.206

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Immunocore Holdings for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=65.292/( ( (50.245 + max(-139.246, 0)) + (49.674 + max(-79.206, 0)) )/ 2 )
=65.292/( ( 50.245 + 49.674 )/ 2 )
=65.292/49.9595
=130.69 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 130.69% mean?
Immunocore Holdings (IMCR) has a ROC (Joel Greenblatt) % of 130.69% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Immunocore Holdings and its competitors. According to the industry distribution chart, Immunocore Holdings ranks #273 out of 1323 companies in the Biotechnology industry, placing it in the top 20.6%.
Is Immunocore Holdings' ROC (Joel Greenblatt) % too high?
Immunocore Holdings' current ROC (Joel Greenblatt) % is 130.69%. Based on the distribution chart, Immunocore Holdings ranks #273 out of 1323 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Immunocore Holdings has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Immunocore Holdings' ROC (Joel Greenblatt) % compare to MAZE and DMRA?
According to the Biotechnology industry distribution chart, Immunocore Holdings ranks #273 out of 1323 companies for ROC (Joel Greenblatt) %. This places Immunocore Holdings in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Immunocore Holdings and its competitors. Immunocore Holdings's current ROC (Joel Greenblatt) % is 130.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunocore Holdings stock overvalued right now?
Based on GuruFocus' analysis, Immunocore Holdings (IMCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $46.28, compared to a current price of $35.54 — trading 23.2% below its estimated fair value. The current ROC (Joel Greenblatt) % is 130.69%. Immunocore Holdings' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Immunocore Holdings (IMCR), the current ROC (Joel Greenblatt) % is 130.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immunocore Holdings (IMCR) Overvalued in 2026?

Based on GuruFocus' analysis, Immunocore Holdings stock appears to be undervalued. The current stock price of $35.54 is trading 23.2% below its estimated GF Value™ of $46.28. GuruFocus considers Immunocore Holdings to be Modestly Undervalued.

Key valuation signals for IMCR:

  • ROC (Joel Greenblatt) %: 130.69%
  • GF Value™: $46.28 vs. price of $35.54 (23.2% below fair value)
  • GF Score™: 76/100 with 3 warning signs

No single metric tells the full story. See the IMCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Immunocore Holdings Business Description

Other Exchanges 6YG:Germany
Address 92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
76GF Score

Get the complete analysis for IMCR

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.54
Price
$46.28
GF Value